FDA Brief

Warning letters Food

FDA warning letter to

NeuroHydrate LLC

MediumIssued Apr 27, 2021Posted May 18, 2021Office of Human and Animal Food Operations East – Division 1

FDA warned NeuroHydrate that its HM-FORMULA supplement is an unapproved new drug because website claims say it prevents migraine.

What happened

In January 2021, FDA reviewed NeuroHydrate's website and found it took orders for HM-FORMULA. The site claimed the product was designed for headache and migraine prevention and to reduce migraine frequency, severity, and duration. FDA said these claims make it a drug, and because it is not generally recognized as safe and effective for those uses, it is a new drug (a product requiring FDA approval before sale) sold without approval.

What FDA found

  1. Website claims say HM-FORMULA is intended to prevent, reduce, or treat headache and migraine, which makes it a drug.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The product is not generally recognized as safe and effective for the claimed headache and migraine uses, so it is a new drug.

    Section 201(p) of the Act [21 U.S.C. 321(p)]
  3. The company introduced or delivered the unapproved new drug into interstate commerce without FDA approval.

    Sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]

What FDA wants

FDA asks NeuroHydrate to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence. If the company believes it is not violating the Act, it must include its reasoning and supporting information; if corrections will take longer, it must explain the delay and completion date.

Who should pay attention

  • dietary supplement brands that make disease claims
  • e-commerce and marketing teams writing product claims
  • companies selling migraine or headache supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk